Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer
DESTINY-Biliary Tract Cancer-01: A Phase 3 Study of Trastuzumab Deruxtecan (T-DXd) and Rilvegostomig Versus Standard-of-Care Gemcitabine, Cisplatin, and Durvalumab for First Line Locally Advanced or Metastatic HER2-expressing Biliary Tract Cancer
AstraZeneca
620 participants
Aug 12, 2024
INTERVENTIONAL
Conditions
Summary
The purpose of this study is to measure the efficacy and safety of T-DXd with rilvegostomig or T-DXd monotherapy compared with gemcitabine plus cisplatin and durvalumab in patients with advanced treatment naïve HER2-expressing BTC.
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Standard of care chemotherapy by intravenous infusion
Standard of care chemotherapy by intravenous infusion
Standard of care immunotherapy by intravenous infusion
Experimental therapy by intravenous infusion
Experimental therapy by intravenous infusion
Locations(270)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06467357